146 related articles for article (PubMed ID: 32559429)
1. Understanding the Deadly Silence of Posterior Fossa A Ependymoma.
Lin GL; Monje M
Mol Cell; 2020 Jun; 78(6):999-1001. PubMed ID: 32559429
[TBL] [Abstract][Full Text] [Related]
2. Into Thin Air: Hypoxia Drives Metabolic and Epigenomic Deregulation of Lethal Pediatric Ependymoma.
Englinger B; Hack OA; Filbin MG
Dev Cell; 2020 Jul; 54(2):134-136. PubMed ID: 32693052
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
Michealraj KA; Kumar SA; Kim LJY; Cavalli FMG; Przelicki D; Wojcik JB; Delaidelli A; Bajic A; Saulnier O; MacLeod G; Vellanki RN; Vladoiu MC; Guilhamon P; Ong W; Lee JJY; Jiang Y; Holgado BL; Rasnitsyn A; Malik AA; Tsai R; Richman CM; Juraschka K; Haapasalo J; Wang EY; De Antonellis P; Suzuki H; Farooq H; Balin P; Kharas K; Van Ommeren R; Sirbu O; Rastan A; Krumholtz SL; Ly M; Ahmadi M; Deblois G; Srikanthan D; Luu B; Loukides J; Wu X; Garzia L; Ramaswamy V; Kanshin E; Sánchez-Osuna M; El-Hamamy I; Coutinho FJ; Prinos P; Singh S; Donovan LK; Daniels C; Schramek D; Tyers M; Weiss S; Stein LD; Lupien M; Wouters BG; Garcia BA; Arrowsmith CH; Sorensen PH; Angers S; Jabado N; Dirks PB; Mack SC; Agnihotri S; Rich JN; Taylor MD
Cell; 2020 Jun; 181(6):1329-1345.e24. PubMed ID: 32445698
[TBL] [Abstract][Full Text] [Related]
4. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.
Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P
Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357
[TBL] [Abstract][Full Text] [Related]
5. Evidence of H3 K27M mutations in posterior fossa ependymomas.
Gessi M; Capper D; Sahm F; Huang K; von Deimling A; Tippelt S; Fleischhack G; Scherbaum D; Alfer J; Juhnke BO; von Hoff K; Rutkowski S; Warmuth-Metz M; Chavez L; Pfister SM; Pietsch T; Jones DT; Sturm D
Acta Neuropathol; 2016 Oct; 132(4):635-7. PubMed ID: 27539613
[No Abstract] [Full Text] [Related]
6. Molecular predictive and prognostic factors in ependymoma.
Benson R; Mallick S; Julka PK; Rath GK
Neurol India; 2016; 64(2):279-86. PubMed ID: 26954807
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
Shu C; Wang Q; Yan X; Wang J
Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
9. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
10. Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort.
Jünger ST; Mynarek M; Wohlers I; Dörner E; Mühlen AZ; Velez-Char N; von Hoff K; Rutkowski S; Warmuth-Metz M; Kortmann RD; Timmermann B; Rahmann S; Klein-Hitpass L; von Bueren AO; Pietsch T
Acta Neuropathol Commun; 2019 Nov; 7(1):181. PubMed ID: 31727173
[TBL] [Abstract][Full Text] [Related]
11. Uncommon pediatric tumors of the posterior fossa: pathologic and molecular features.
Dunham C
Childs Nerv Syst; 2015 Oct; 31(10):1729-37. PubMed ID: 26351226
[TBL] [Abstract][Full Text] [Related]
12. Recurrent ACVR1 mutations in posterior fossa ependymoma.
Pratt D; Lucas CG; Selvam PP; Abdullaev Z; Ketchum C; Quezado M; Armstrong TS; Gilbert MR; Papanicolau-Sengos A; Raffeld M; Choo-Wosoba H; Chan P; Whipple N; Nasrallah M; Santi M; Ramaswamy V; Giannini C; Ritzmann TA; Grundy RG; Burford A; Jones C; Hawkins C; Venneti S; Solomon DA; Aldape K
Acta Neuropathol; 2022 Aug; 144(2):373-376. PubMed ID: 35587280
[No Abstract] [Full Text] [Related]
13. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas.
Puget S; Grill J; Valent A; Bieche I; Dantas-Barbosa C; Kauffmann A; Dessen P; Lacroix L; Geoerger B; Job B; Dirven C; Varlet P; Peyre M; Dirks PB; Sainte-Rose C; Vassal G
J Clin Oncol; 2009 Apr; 27(11):1884-92. PubMed ID: 19289631
[TBL] [Abstract][Full Text] [Related]
14. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.
Pierce AM; Witt DA; Donson AM; Gilani A; Sanford B; Sill M; Van Court B; Oweida A; Prince EW; Steiner J; Danis E; Dorris K; Hankinson T; Handler MH; Jones KL; Karam SD; Serkova NJ; Vibhakar R; Foreman NK; Griesinger AM
Neuro Oncol; 2019 Dec; 21(12):1540-1551. PubMed ID: 31276586
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
17. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
18. TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma.
Pierscianek D; Teuber-Hanselmann S; Ahmadipour Y; Darkwah Oppong M; Unteroberdörster M; Müller O; Jabbarli R; Sure U; Zhu Y; El Hindy N
Neuropathology; 2020 Apr; 40(2):138-143. PubMed ID: 31777116
[TBL] [Abstract][Full Text] [Related]
19. Posterior fossa ependymoma: current insights.
Thompson YY; Ramaswamy V; Diamandis P; Daniels C; Taylor MD
Childs Nerv Syst; 2015 Oct; 31(10):1699-706. PubMed ID: 26351223
[TBL] [Abstract][Full Text] [Related]
20. Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma.
Zhang C; Ostrom QT; Semmes EC; Ramaswamy V; Hansen HM; Morimoto L; de Smith AJ; Pekmezci M; Vaksman Z; Hakonarson H; Diskin SJ; Metayer C; ; Taylor MD; Wiemels JL; Bondy ML; Walsh KM
Acta Neuropathol Commun; 2020 Oct; 8(1):173. PubMed ID: 33115534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
